How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors

Tarsus Pharmaceuticals recently dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults ...

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., ...